According to a new study published in the journal Epilepsy & Behavior, abruptly stopping the use of CBD (cannabidiol) is not associated with physical withdrawal symptoms. The study is titled Abrupt withdrawal of cannabidiol (CBD): A randomized trial.
For the study researchers examined the occurrence of withdrawal symptoms induced by the abrupt cessation of CBD, reports NORML. Subjects in the trial were healthy volunteers who ingested 750mg of plant-derived CBD twice daily for a period of four weeks. Study participants either continued to receive CBD or received a placebo during weeks five and six. Researchers reported no serious adverse events resulting from the discontinuation of CBD.
They found that “In healthy volunteers, no evidence of withdrawal syndrome was found with abrupt discontinuation of short-term treatment with CBD.”
As noted by NORML, in 2018, federal regulators classified Epidiolex – an FDA-approved formulation of plant-derived CBD – as a Schedule V substance, the lowest restriction classification available under federal law.
The study’s full abstract is listed below: